Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis
Barrett W Jeffers, Rahul Bhambri, Jeffery Robbins Pfizer Inc., New York, NY, USA Abstract: Diabetic patients with hypertension are approximately twice as likely to develop cardiovascular disease as non-diabetic patients with hypertension. Given that hypertension affects ~60% of patients with diabet...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-11-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/uptitrating-amlodipine-significantly-reduces-blood-pressure-in-diabeti-peer-reviewed-article-VHRM |
| _version_ | 1818334704865116160 |
|---|---|
| author | Jeffers BW Bhambri R Robbins J |
| author_facet | Jeffers BW Bhambri R Robbins J |
| author_sort | Jeffers BW |
| collection | DOAJ |
| description | Barrett W Jeffers, Rahul Bhambri, Jeffery Robbins Pfizer Inc., New York, NY, USA Abstract: Diabetic patients with hypertension are approximately twice as likely to develop cardiovascular disease as non-diabetic patients with hypertension. Given that hypertension affects ~60% of patients with diabetes, effective blood pressure (BP) management is important in this high-risk population. This post-hoc analysis pooled data from six clinical studies to quantify additional BP efficacy achieved when titrating hypertensive diabetic patients from amlodipine 5 mg to 10 mg. Approximately half of the diabetic patients were male (44/98; 44.9%) with a mean (standard deviation [SD]) age of 60.6 (9.6) years and a baseline mean (standard error [SE]) systolic blood pressure/diastolic blood pressure (SBP/DBP) of 150.8 (1.30)/87.5 (0.94) mmHg while on amlodipine 5 mg (159.1 [1.40]/92.6 [0.94] mmHg prior to treatment). In comparison, 350/610 (57.4%) non-diabetic patients were male with a mean (SD) age of 58.7 (11.1) years and baseline mean (SE) SBP/DBP of 150.3 (0.62)/90.9 (0.41) mmHg while on amlodipine 5 mg (160.0 [0.67]/96.2 [0.45] mmHg prior to treatment). Increasing amlodipine from 5 mg to 10 mg lowered sitting SBP by -12.5 mmHg (95% confidence interval (CI): -15.5, -9.5; P<0.0001) and DBP by -6.0 mmHg (-7.4, -4.6; P<0.0001) in diabetic patients; and SBP by -12.4 mmHg (-13.5, -11.3; P<0.0001) and DBP by -7.3 mmHg (-8.0, -6.7; P<0.0001) in non-diabetic patients. In total, 12.0% (95% CI: 6.4, 20.0) of diabetic patients achieved their BP goal versus 46.4% (42.4, 50.4) of non-diabetic patients after titration to amlodipine 10 mg. Overall, 22.0% of diabetic patients experienced 31 adverse events (AEs) and 28.9% of non-diabetic patients experienced 282 AEs. Serious AEs were reported by one (1.0%) diabetic and five (0.8%) non-diabetic patients. In this analysis, increasing amlodipine from 5 mg to 10 mg produced a clinically significant reduction in the BP of diabetic hypertensive patients, similar to non-diabetic patients, highlighting the importance of optimizing amlodipine titration in this high-risk population. Keywords: hypertension, diabetes, calcium channel blockers, cardiovascular disease prevention, efficacy |
| first_indexed | 2024-12-13T14:11:46Z |
| format | Article |
| id | doaj.art-f1248585ed9445cebceedb80a4ed93d4 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-13T14:11:46Z |
| publishDate | 2014-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-f1248585ed9445cebceedb80a4ed93d42022-12-21T23:42:27ZengDove Medical PressVascular Health and Risk Management1178-20482014-11-012014default65165919165Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysisJeffers BWBhambri RRobbins JBarrett W Jeffers, Rahul Bhambri, Jeffery Robbins Pfizer Inc., New York, NY, USA Abstract: Diabetic patients with hypertension are approximately twice as likely to develop cardiovascular disease as non-diabetic patients with hypertension. Given that hypertension affects ~60% of patients with diabetes, effective blood pressure (BP) management is important in this high-risk population. This post-hoc analysis pooled data from six clinical studies to quantify additional BP efficacy achieved when titrating hypertensive diabetic patients from amlodipine 5 mg to 10 mg. Approximately half of the diabetic patients were male (44/98; 44.9%) with a mean (standard deviation [SD]) age of 60.6 (9.6) years and a baseline mean (standard error [SE]) systolic blood pressure/diastolic blood pressure (SBP/DBP) of 150.8 (1.30)/87.5 (0.94) mmHg while on amlodipine 5 mg (159.1 [1.40]/92.6 [0.94] mmHg prior to treatment). In comparison, 350/610 (57.4%) non-diabetic patients were male with a mean (SD) age of 58.7 (11.1) years and baseline mean (SE) SBP/DBP of 150.3 (0.62)/90.9 (0.41) mmHg while on amlodipine 5 mg (160.0 [0.67]/96.2 [0.45] mmHg prior to treatment). Increasing amlodipine from 5 mg to 10 mg lowered sitting SBP by -12.5 mmHg (95% confidence interval (CI): -15.5, -9.5; P<0.0001) and DBP by -6.0 mmHg (-7.4, -4.6; P<0.0001) in diabetic patients; and SBP by -12.4 mmHg (-13.5, -11.3; P<0.0001) and DBP by -7.3 mmHg (-8.0, -6.7; P<0.0001) in non-diabetic patients. In total, 12.0% (95% CI: 6.4, 20.0) of diabetic patients achieved their BP goal versus 46.4% (42.4, 50.4) of non-diabetic patients after titration to amlodipine 10 mg. Overall, 22.0% of diabetic patients experienced 31 adverse events (AEs) and 28.9% of non-diabetic patients experienced 282 AEs. Serious AEs were reported by one (1.0%) diabetic and five (0.8%) non-diabetic patients. In this analysis, increasing amlodipine from 5 mg to 10 mg produced a clinically significant reduction in the BP of diabetic hypertensive patients, similar to non-diabetic patients, highlighting the importance of optimizing amlodipine titration in this high-risk population. Keywords: hypertension, diabetes, calcium channel blockers, cardiovascular disease prevention, efficacyhttp://www.dovepress.com/uptitrating-amlodipine-significantly-reduces-blood-pressure-in-diabeti-peer-reviewed-article-VHRM |
| spellingShingle | Jeffers BW Bhambri R Robbins J Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis Vascular Health and Risk Management |
| title | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis |
| title_full | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis |
| title_fullStr | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis |
| title_full_unstemmed | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis |
| title_short | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis |
| title_sort | uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension a retrospective pooled analysis |
| url | http://www.dovepress.com/uptitrating-amlodipine-significantly-reduces-blood-pressure-in-diabeti-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT jeffersbw uptitratingamlodipinesignificantlyreducesbloodpressureindiabeticpatientswithhypertensionaretrospectivepooledanalysis AT bhambrir uptitratingamlodipinesignificantlyreducesbloodpressureindiabeticpatientswithhypertensionaretrospectivepooledanalysis AT robbinsj uptitratingamlodipinesignificantlyreducesbloodpressureindiabeticpatientswithhypertensionaretrospectivepooledanalysis |